Transitioning from Part D to Part B: A Medicare Story
Author: Jeffrey L. Hymes, MD, CMO & SVP Following the U.S. Food and Drug Administration’s recent approval of Parsabiv™ (etelcalcetide),...
Intravenous Form of Sensipar® Has Been Approved by the FDA
Author: Jeffrey L. Hymes, MD, CMO & SVP Parsabiv™, an IV formulation similar to the oral calcimimetic Sensipar®, was recently...